Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that lecanemab, an anti-amyloid-β protofibril antibody being developed by Eisai, has no connection regarding an article published in the US scientific journal Science on July 22, 2022.

This article reported that a research paper on Aβ*56, a type of Aβ oligomer, is under investigation for its credibility, but this case has no relation to lecanemab.

Lecanemab showed a correlation between Aβ removal and a slower clinical decline in Study 201, and the Phase III study Clarity AD is currently underway.

We will continue to make every effort to deliver a new treatment as soon as possible to Alzheimer's disease patients, their families, and medical professionals.